Background: Immunoglobulin G4 (IgG4)-related diseases are a group of diseases characterized by enlargement of the affected organs, elevation of serum IgG4, massive infiltration of affected organs with lymphocytes and plasma cells with IgG4 positivity and tissue fibrosis. Type I autoimmune pancreatitis is one form of IgG4-related disease. For IgG4-related diseases, various localizations are described for up to 10% of malignancies. The aim of our study was to examine IgG4 serum levels and pancreatic tissue with respect to the simultaneous presence of autoimmune pancreatitis in patients with pancreatic cancer. Methods: IgG4 serum levels were examined In 106 patients with histologically confirmed pancreatic cancer. The level of 135 mg/dl was considered as the normal value. Pancreatic tissue was histologically examined with respect to the presence of markers of autoimmune pancreatitis. Results: A higher IgG4 level than the cut-off value of 135 mg/dl was proven in 11 patients with pancreatic cancer. Of these 11 patients, 7 had levels twice the normal limit (65.6%). Autoimmune pancreatitis was diagnosed in these individuals. In the case of 1 patient, it was basically an unexpected finding; another patient was initially diagnosed with autoimmune pancreatitis. Repeated biopsy of the pancreas at the time of diagnosis did not confirm the presence of tumour structures, therefore steroid therapy was started. At a check-up 6 months after starting steroid therapy, the condition of the patient improved subjectively and IgG4 levels decreased. However, endosonographically, malignancy was suspected, which was subsequently confirmed histologically. This patient also demonstrated an IgG4 level twice the normal limit. Conclusion: IgG4-related diseases can be accompanied by the simultaneous occurrence of malignancies, which also applies to autoimmune pancreatitis. Chronic pancreatitis is considered a risk factor for pancreatic cancer. It cannot be reliably confirmed whether this also applies to autoimmune pancreatitis. In accordance with other works, however, it is evident that, despite the described high sensitivity and specificity for IgG4 elevation in the case of autoimmune pancreatitis, even levels twice the normal limit are demonstrable in some individuals with pancreatic cancer, without the presence of autoimmune pancreatitis. We believe that patients with IgG4-related disease, including autoimmune pancreatitis, must be systematically monitored with respect to the potential presence of malignancy.

Keywords:
Immunoglobulin G4, Autoimmune pancreatitis, Pancreatic cancer
1.
Takahashi H, Yamamoto M, Suzuki C, et al: The birthday of a new syndrome: IgG4-related disease constitutes a clinical entity. Autoimmune Rev 2010;9:591-594.
2.
Vlachou PA, Khalili K, Jang H-J, et al: IgG4-related sclerosing disease: autoimmune pancreatitis and extrapancreatic manifestations. Radiographics 2011;31:1379-1402.
3.
Hamano H, Kawa S, Hirouchi A, et al: High serum IgG4 concentration in patients with sclerosing pancreatitis. N. Engl. J. Med 2001;344:732-738.
4.
Kamisawa T, Chen PY, Tu Y, et al: Pancreatic cancer with a serum IgG4 concentration. World J Gastroenterol 2006;12:6225-6228.
5.
Yamamoto M, Takahashi H, Tabeya T, et al: Risk of malignancies in IgG4-related disease. Mod Rheumatol 2012;22:414-418.
6.
Inoue H, Miyatani H, Sawada Y: A case of pancreatic cancer with autoimmune pancreatitis. Pancreas 2006;33:208-209.
7.
Wilkiewicz AK, Kennedy EP, Keneyon I, et al: Synchronous autoimmune pancreatitis and infiltrating pancreatic ductal adenocarcinoma: case report and review of the literature. Human Pathol 2008;39:1548-1551.
8.
Raina A, Krasinskas AM, Greer JB, et al: Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis. Arch Pathol Lab Med 2007;112:48-53.
9.
Umehara M, Okazaki K, Masaki Y, et al: Comprehensive diagnostic criteria for IgG4-related disease. Mod Rheumatol 2012;22:21-30.
10.
Pezzilli R, Vecchiarelli S, DiMarco MC, et al: Pancreatic ductal adenocarcinoma related with autoimmune pancreatitis. Case Rep Gastroenterol 2011;5:378-385.
11.
Loos M, Esposito I, Hedderich DM, et al: Autoimmune pancreatitis complicated by carcinoma of the pancreatobiliary system. Pancreas 2011;40:151-154.
12.
Shimozegawa T, Chari ST, Frulloni L, et al: International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 2011;40:352-358.
13.
Kamisawa T, Chari ST, Lerch MM, et al: Recent advances in autoimmune pancreatitis type 1 and type 2. Gut 2013;62:1373-1380.
14.
Psarras K, Baltatris MF, Pavlidis ET: Autoimmune pancreatitis versus pancreatic cancer a comprehensive review with emphasis on differential diagnosis. Hepatobiliary Pancreat Dis Int 2011;10:465-473.
15.
Ghazale A, Chari ST, Smyrk TC, et al: Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol 2007;102:1646-1653.
16.
Siokawa M, Kodama Y, Ypshimura K, et al: Risk of cancer in patients with autoimmune pancreatitis. Am J Gastroenterol 2013;108: 610-618.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.